FDA’s Sneaky 'Pass' Lets Sketchy India-Made Drugs Crash US Party

Since 2013, the FDA has been starring in its own spy thriller, quietly letting over 20 troubled overseas drug factories—mostly hosting drama-filled performances in India—skip import bans despite bans for contamination and quality flops. Senators Rick Scott (R-Fla.) and Kirsten Gillibrand (D-N.Y.), the dynamic bipartisan duo on the Senate Special Committee on Aging, are finally raising the alarm about this covert backdoor operation. They want Congress and hospitals in the loop instead of the FDA playing hide and seek. India's generic drugs supply half the US, with China ghost-producing key ingredients. Meanwhile, the Department of Defense reports potency fouls with drugs meant for service members, but the FDA insists they did 'extra quality testing'—invisible to anyone outside their secret club. Retired Army Col. Vic Suarez warns this new 'federal buyer’s market' strategy could shake US healthcare like never before. Oh, and companies might soon have to slap 'Made In USA' labels on those meds, so no more guessing games where your life-saving pills were born. Because nothing says patient comfort like a dose of geopolitical tension.

Share the Story

(1 of 3)
Swipe to navigate

Source: Propublica | Published: 10/27/2025 | Author: by Debbie Cenziper and Megan Rose, ProPublica, and Melissa Dai, Medill Investigative Lab